Ola Landgren

Ola Landgren is an internationally recognized leader in myeloma minimal residual disease (MRD) and the biology of precursor plasma cell diseases. He pioneered the application of next-generation sequencing-based MRD testing (clonoSEQ) as a sensitive and specific endpoint in myeloma clinical trials, contributing to its FDA clearance. His epidemiologic work established that virtually all myeloma is preceded by MGUS or SMM, creating a framework for cancer prevention. He led clinical trials of first-line quadruplet therapy with MRD-driven endpoints and has authored influential consensus recommendations for MRD standardization.